Erasca (ERAS) has entered a clinical trial collaboration and supply agreement with Merck (MRK) to study its investigational drug ERAS-0015 in combination with Keytruda in patients with RAS-mutant solid tumors, the company said Monday.

Under the agreement, Erasca will sponsor the AURORAS-1 clinical proof-of-concept study, while Merck will supply Keytruda at no cost.

The trial will assess whether Erasca's ERAS-0015, a pan-RAS molecular glue, can enhance PD-1 blockade by reducing tumor-induced immune suppression and improving response durability in RAS/MAPK-driven cancers, the company said.

Shares of Erasca were up 4.7% in premarket activity Monday.